CI-988 Inhibits EGFR Transactivation and Proliferation Caused by Addition of CCK/Gastrin to Lung Cancer Cells

Overview

Journal J Mol Neurosci

Specialties Molecular Biology
Neurology

Date 2015 Mar 13

PMID 25761747

Citations 9

Authors

Terry W Moody

Bernardo Nuche-Berenguer

Paola Moreno

Robert T Jensen

Affiliations

Soon will be listed here.

Abstract

Cholecystokinin (CCK) receptors are G-protein coupled receptors (GPCR) which are present on lung cancer cells. CCK-8 stimulates the proliferation of lung cancer cells, whereas the CCK2R receptor antagonist CI-988 inhibits proliferation. GPCR for some gastrointestinal hormones/neurotransmitters mediate lung cancer growth by causing epidermal growth factor receptor (EGFR) transactivation. Here, the role of CCK/gastrin and CI-988 on EGFR transactivation and lung cancer proliferation was investigated. Addition of CCK-8 or gastrin-17 (100 nM) to NCI-H727 human lung cancer cells increased EGFR Tyr(1068) phosphorylation after 2 min. The ability of CCK-8 to cause EGFR tyrosine phosphorylation was blocked by CI-988, gefitinib (EGFR tyrosine kinase inhibitor), PP2 (Src inhibitor), GM6001 (matrix metalloprotease inhibitor), and tiron (superoxide scavenger). CCK-8 nonsulfated and gastrin-17 caused EGFR transactivation and bound with high affinity to NCI-H727 cells, suggesting that the CCK2R is present. CI-988 inhibited the ability of CCK-8 to cause ERK phosphorylation and elevate cytosolic Ca(2+). CI-988 or gefitinib inhibited the basal growth of NCI-H727 cells or that stimulated by CCK-8. The results indicate that CCK/gastrin may increase lung cancer proliferation in an EGFR-dependent manner.

Citing Articles

Deciphering Aflatoxin B1 affected critical molecular pathways governing cancer: A bioinformatics study using CTD and PANTHER databases.

Kapri A, Singh D, Onteru S Mycotoxin Res. 2024; 41(1):93-111.

PMID: 39417919 DOI: 10.1007/s12550-024-00563-0.

Construction and analysis of the ceRNA network in lung adenocarcinoma.

Yang Y, Zhang Y, Ding X, Ren Y, Wei B, Lin Z Ann Transl Med. 2022; 9(24):1757.

PMID: 35071451 PMC: 8756233. DOI: 10.21037/atm-21-5854.

Knockdown of Gastrin Promotes Apoptosis of Gastric Cancer Cells by Decreasing ROS Generation.

Liu Y, Zhu J, Liu J, Ma X, Zhao J, Su Z Biomed Res Int. 2021; 2021:5590037.

PMID: 33937399 PMC: 8062189. DOI: 10.1155/2021/5590037.

The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC).

Hsu P, Yang C, Jablons D, You L Cancers (Basel). 2020; 12(6).

PMID: 32466572 PMC: 7352956. DOI: 10.3390/cancers12061361.

RGS4 Regulates Proliferation And Apoptosis Of NSCLC Cells Via microRNA-16 And Brain-Derived Neurotrophic Factor.

He Z, Yu L, Luo S, Li Q, Huang S, An Y Onco Targets Ther. 2019; 12:8701-8714.

PMID: 31695428 PMC: 6821062. DOI: 10.2147/OTT.S221657.

References

Seva C, Kowalski-Chauvel A, Daulhac L, Barthez C, Vaysse N, Pradayrol L . Wortmannin-sensitive activation of p70S6-kinase and MAP-kinase by the G protein-coupled receptor, G/CCKB. Biochem Biophys Res Commun. 1997; 238(1):202-6. DOI: 10.1006/bbrc.1997.7163. View

Tsutsui S, Shinomura Y, Higashiyama S, Higashimoto Y, Miyazaki Y, Kanayama S . Induction of heparin binding epidermal growth factor-like growth factor and amphiregulin mRNAs by gastrin in the rat stomach. Biochem Biophys Res Commun. 1997; 235(3):520-3. DOI: 10.1006/bbrc.1997.6824. View

Paulssen R, Fraeyman N, Florholmen J . Activation of phospholipase C by cholecystokinin receptor subtypes with different G-protein-coupling specificities in hormone-secreting pancreatic cell lines. Biochem Pharmacol. 2000; 60(6):865-75. DOI: 10.1016/s0006-2952(00)00383-x. View

Ahmed S, Coulson J, Woll P . Use of RT-PCR to detect co-expression of neuropeptides and their receptors in lung cancer. Lung Cancer. 2001; 33(1):1-9. DOI: 10.1016/s0169-5002(00)00248-8. View

Moody T, Jensen R . CI-988 inhibits growth of small cell lung cancer cells. J Pharmacol Exp Ther. 2001; 299(3):1154-60. View

Clerc P, Leung-Theung-Long S, Wang T, Dockray G, Bouisson M, Delisle M . Expression of CCK2 receptors in the murine pancreas: proliferation, transdifferentiation of acinar cells, and neoplasia. Gastroenterology. 2002; 122(2):428-37. DOI: 10.1053/gast.2002.30984. View

Wroblewski L, Pritchard D, Carter S, Varro A . Gastrin-stimulated gastric epithelial cell invasion: the role and mechanism of increased matrix metalloproteinase 9 expression. Biochem J. 2002; 365(Pt 3):873-9. PMC: 1222716. DOI: 10.1042/BJ20020068. View

Coulson J, Ocejo-Garcia M, Woll P . Neuroendocrine phenotype of small cell lung cancer. Methods Mol Med. 2002; 74:61-73. DOI: 10.1385/1-59259-323-2:61. View

Guo Y, Cheng J, Jin G, Gutkind J, Hellmich M, Townsend Jr C . Gastrin stimulates cyclooxygenase-2 expression in intestinal epithelial cells through multiple signaling pathways. Evidence for involvement of ERK5 kinase and transactivation of the epidermal growth factor receptor. J Biol Chem. 2002; 277(50):48755-63. DOI: 10.1074/jbc.M209016200. View

10.

Piiper A, Elez R, You S, Kronenberger B, Loitsch S, Roche S . Cholecystokinin stimulates extracellular signal-regulated kinase through activation of the epidermal growth factor receptor, Yes, and protein kinase C. Signal amplification at the level of Raf by activation of protein kinase Cepsilon. J Biol Chem. 2002; 278(9):7065-72. DOI: 10.1074/jbc.M211234200. View

11.

Sinclair N, Ai W, Raychowdhury R, Bi M, Wang T, Koh T . Gastrin regulates the heparin-binding epidermal-like growth factor promoter via a PKC/EGFR-dependent mechanism. Am J Physiol Gastrointest Liver Physiol. 2004; 286(6):G992-9. DOI: 10.1152/ajpgi.00206.2002. View

12.

Lynch T, Bell D, Sordella R, Gurubhagavatula S, Okimoto R, Brannigan B . Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350(21):2129-39. DOI: 10.1056/NEJMoa040938. View

13.

Gibbs J, Young R, Smith G . Cholecystokinin elicits satiety in rats with open gastric fistulas. Nature. 1973; 245(5424):323-5. DOI: 10.1038/245323a0. View

14.

Mutt V, JORPES E . Hormonal polypeptides of the upper intestine. Biochem J. 1971; 125(3):57P-58P. PMC: 1178208. DOI: 10.1042/bj1250057p. View

15.

Paez J, Janne P, Lee J, Tracy S, Greulich H, Gabriel S . EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304(5676):1497-500. DOI: 10.1126/science.1099314. View

16.

Jensen R, Lemp G, Gardner J . Interaction of cholecystokinin with specific membrane receptors on pancreatic acinar cells. Proc Natl Acad Sci U S A. 1980; 77(4):2079-83. PMC: 348655. DOI: 10.1073/pnas.77.4.2079. View

17.

Innis R, Snyder S . Distinct cholecystokinin receptors in brain and pancreas. Proc Natl Acad Sci U S A. 1980; 77(11):6917-21. PMC: 350402. DOI: 10.1073/pnas.77.11.6917. View

18.

Wang R, Hu X . Does cholecystokinin potentiate dopamine action in the nucleus accumbens?. Brain Res. 1986; 380(2):363-7. DOI: 10.1016/0006-8993(86)90236-2. View

19.

Yoder D, Moody T . High affinity binding of cholecystokinin to small cell lung cancer cells. Peptides. 1987; 8(1):103-7. DOI: 10.1016/0196-9781(87)90171-9. View

20.

Crawley J . Modulation of mesolimbic dopaminergic behaviors by cholecystokinin. Ann N Y Acad Sci. 1988; 537:380-96. DOI: 10.1111/j.1749-6632.1988.tb42121.x. View